Literature DB >> 27498392

An early dysregulation of FAK and MEK/ERK signaling pathways precedes the β-amyloid deposition in the olfactory bulb of APP/PS1 mouse model of Alzheimer's disease.

Mercedes Lachén-Montes1, Andrea González-Morales1, Xabier Martínez de Morentin2, Estela Pérez-Valderrama2, Karina Ausín2, María Victoria Zelaya1, Antonio Serna3, Ester Aso4, Isidro Ferrer4, Joaquín Fernández-Irigoyen5, Enrique Santamaría6.   

Abstract

UNLABELLED: Olfactory dysfunction is an early event of Alzheimer's disease (AD). However, the mechanisms associated to AD neurodegeneration in olfactory areas are unknown. Here we used double-transgenic amyloid precursor protein/presenilin 1 (APPswe/PS1dE9) mice and label-free quantitative proteomics to analyze early pathological effects on the olfactory bulb (OB) during AD progression. Prior to β-amyloid plaque formation, 9 modulated proteins were detected on 3-month-old APP/PS1 mice while 16 differential expressed proteins were detected at 6months, when β-amyloid plaques appear, indicating a moderate imbalance in cytoskeletal rearrangement, and synaptic plasticity in APP/PS1 OBs. Moreover, β-amyloid induced an inactivation of focal adhesion kinase (FAK) together with a transient activation of MEK1/2, leading to inactivation of ERK1/2 in 6-months APP/PS1 OBs. In contrast, the analysis of human OBs revealed a late activation of FAK in advanced AD stages, whereas ERK1/2 activation was enhanced across AD staging respect to controls. This survival potential was accompanied by the inhibition of the proapototic factor BAD in the OB across AD phenotypes. Our data contribute to a better understanding of the early molecular mechanisms that are modulated in AD neurodegeneration, highlighting significant differences in the regulation of survival pathways between APP/PS1 mice and sporadic human AD. SIGNIFICANCE: Loss of smell is involved in early stages of Alzheimer's disease (AD), usually preceding classic disease symptoms. However, the mechanisms governing this dysfunction are still poorly understood, losing its potential as a useful tool for clinical diagnosis. Our study characterizes potential AD-associated molecular changes in APP/PS1 mice olfactory bulb (OB) using MS-quantitative proteomics, revealing early cytoskeletal disruption and synaptic plasticity impairment. Moreover, an opposite pattern was found when comparing the activation status of specific survival pathways between APP/PS1 OBs and OBs derived from sAD subjects with different neuropathological grading. Our data reflect, in part, the progressive effect of APP overproduction and Aβ accumulation on the OB proteome during AD progression.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  APP/PS1 model; Alzheimer; Brain; Olfactory bulb; Proteomics

Mesh:

Substances:

Year:  2016        PMID: 27498392     DOI: 10.1016/j.jprot.2016.07.032

Source DB:  PubMed          Journal:  J Proteomics        ISSN: 1874-3919            Impact factor:   4.044


  13 in total

1.  Gestational Stress Augments Postpartum β-Amyloid Pathology and Cognitive Decline in a Mouse Model of Alzheimer's Disease.

Authors:  Zahra Jafari; Jogender Mehla; Bryan E Kolb; Majid H Mohajerani
Journal:  Cereb Cortex       Date:  2019-08-14       Impact factor: 5.357

2.  Injected Amyloid Beta in the Olfactory Bulb Transfers to Other Brain Regions via Neural Connections in Mice.

Authors:  Baixuan He; Minying Zheng; Qiang Liu; Zhe Shi; Simei Long; Xilin Lu; Zhong Pei; Ti-Fei Yuan; Huanxing Su; Xiaoli Yao
Journal:  Mol Neurobiol       Date:  2017-02-16       Impact factor: 5.590

3.  O-GlcNAcylation regulates integrin-mediated cell adhesion and migration via formation of focal adhesion complexes.

Authors:  Zhiwei Xu; Tomoya Isaji; Tomohiko Fukuda; Yuqin Wang; Jianguo Gu
Journal:  J Biol Chem       Date:  2018-12-26       Impact factor: 5.157

4.  Dysregulated Brain Protein Phosphorylation Linked to Increased Human Tau Expression in the hTau Transgenic Mouse Model.

Authors:  Isidro Ferrer; Pol Andrés-Benito; Karina Ausín; Paz Cartas-Cejudo; Mercedes Lachén-Montes; José Antonio Del Rio; Joaquín Fernández-Irigoyen; Enrique Santamaría
Journal:  Int J Mol Sci       Date:  2022-06-08       Impact factor: 6.208

5.  Olfactory bulb neuroproteomics reveals a chronological perturbation of survival routes and a disruption of prohibitin complex during Alzheimer's disease progression.

Authors:  Mercedes Lachén-Montes; Andrea González-Morales; María Victoria Zelaya; Estela Pérez-Valderrama; Karina Ausín; Isidro Ferrer; Joaquín Fernández-Irigoyen; Enrique Santamaría
Journal:  Sci Rep       Date:  2017-08-22       Impact factor: 4.379

Review 6.  Amyloid-beta immunotherapy: the hope for Alzheimer disease?

Authors:  Alvaro Barrera-Ocampo; Francisco Lopera
Journal:  Colomb Med (Cali)       Date:  2016-12-30

Review 7.  "Till Death Do Us Part": A Potential Irreversible Link Between Aberrant Cell Cycle Control and Neurodegeneration in the Adult Olfactory Bulb.

Authors:  Saad Omais; Carine Jaafar; Noël Ghanem
Journal:  Front Neurosci       Date:  2018-03-09       Impact factor: 4.677

8.  Huatuo Zaizao pill ameliorates cognitive impairment of APP/PS1 transgenic mice by improving synaptic plasticity and reducing Aβ deposition.

Authors:  Jing-Hua Zhang; Lin-Jie Yu; Hui Yang; Zhen Hui; Su Jiang; Ling Chen; Yang Zhao; Su-Lei Wang; Yi Liu; Yun Xu
Journal:  BMC Complement Altern Med       Date:  2018-05-29       Impact factor: 3.659

9.  Network-Driven Proteogenomics Unveils an Aging-Related Imbalance in the Olfactory IκBα-NFκB p65 Complex Functionality in Tg2576 Alzheimer's Disease Mouse Model.

Authors:  Maialen Palomino-Alonso; Mercedes Lachén-Montes; Andrea González-Morales; Karina Ausín; Alberto Pérez-Mediavilla; Joaquín Fernández-Irigoyen; Enrique Santamaría
Journal:  Int J Mol Sci       Date:  2017-10-27       Impact factor: 5.923

10.  The Membrane Glycoprotein M6a Endocytic/Recycling Pathway Involves Clathrin-Mediated Endocytosis and Affects Neuronal Synapses.

Authors:  Micaela D Garcia; Karina Formoso; Gabriela I Aparicio; Alberto C C Frasch; Camila Scorticati
Journal:  Front Mol Neurosci       Date:  2017-09-20       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.